New ibezapolstat trial announcement for recurrent CDI fueled continued momentum and 46% intraday surge.
The March 9 premarket press release detailed an open-label pilot trial enrolling up to 20 patients with multiply-recurrent C. difficile infections (at least three episodes in 12 months), with startup activities beginning later in March 2026 and first dosing in Q4. This builds on Phase 2 data showing 96% clinical cure rates and zero recurrences, positioning the drug for potential FDA approval under the Limited Population Pathway as a single-agent treatment and prevention option. High trading volume and retail trader chatter amplified the prior day's 31% gain into today's breakout, with shares ripping toward $3 amid low-float biotech momentum.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.